CPA-7

CPA7 is a novel Stat3 inhibitor. CPA7 downregulates survivin, Bcl-XL, and Mcl-1. CPA7 induces Apoptosis. CPA7 enhances the radiosensitivity of prostate cancer. CPA7 has anti-cancer effects against prostate cancer[1][2].

Product Specifications

CAS Number

16961-77-6

UNSPSC

12352100

Target

Apoptosis; Bcl-2 Family; STAT; Survivin

Related Pathways

Apoptosis; JAK/STAT Signaling; Stem Cell/Wnt

Field of Research

Cancer

Smiles

O=[N-]([Pt+4]([Cl-])([Cl-])([NH3])([NH3])[Cl-])=O

Molecular Formula

Cl3H6N3O2Pt

Molecular Weight

381.51

References & Citations

[1]Sekharam M, et al. CPA7, a novel Stat3 inhibitor radiosensitizes prostate cancer cells. International Journal of Radiation Oncology, Biology, Physics, 2005, 63: S483.|[2]Liang M, et al. CPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3. BMC Cancer. 2016 Jul 19;16:504.